ERBB2 and breast cancer: Kaplan–Meier survival analysis showed that the median survival times of patients with human epidermal growth factor receptor 2 (HER2)-positive, luminal A, luminal B, and triple-negative BC were 25 (95% confidence interval [CI], 20–37), 27 (95% CI, 23–29), 35 (95% CI, 30–44), and 12 (95% CI, 11–14), respectively.